gies that have helped improve the lives of millions of people worldwide. With four key focus areas – Ostomy Care, Wound Therapeutics, Continence and Critical Care, and Infusion Devices – ConvaTec products support healthcare professionals from the hospital to the community health setting. For more information, please visit www.convatec.com
(1) HPIS. Q2 2009. Moving Annual Total (MAT) Fecal Control Category. Data on file, ConvaTec.
(2) Jones S, Towers V, Welsby S, Wishin J, Bowler P. Clostridium difficile Containment Properties of a Fecal Management System: An In Vitro Investigation. Ostomy Wound Management, 2011;57(10):38-49.
(3) Padmanabhan A, Stern M, Wishin J, Mangino M, Richey K, DeSane M. Clinical evaluation of a flexible fecal incontinence management system. Am J Crit Care, July 2007;16:384-393.
®/™ indicates trademarks of ConvaTec Inc.
© 2012 ConvaTec Inc. Page: 1 2 3 Related medicine technology :1
. ConvaTec Announces Acquisition of AbViser Medical, LLC2
. ConvaTec Donates $10,000 To AAWC Global Volunteers Program Through SAWC Walk For Wellness3
. IDEV Technologies Introduces SurePath™ Guidewires4
. Velos, Inc. Introduces Mobile App for Oncology Adverse Events and Graft-Versus-Host Disease at 2012 ASCO Annual Meeting5
. Rochester Medical Introduces Magic3® Coude Tip Hydrophilic Intermittent Catheter6
. Richard Wolf Medical Instruments introduces groundbreaking 5514 Endocam Performance HD7
. Pernix Therapeutics Introduces Omeclamox-Pak®, First Product in Gastroenterology Portfolio8
. IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma9
. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma10
. PharMEDium Highlights Enhanced Labeling for ICU Services at Critical Care Expo11
. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)